Nuwellis Transitions Leadership with Nestor Jaramillo's Retirement
MINNEAPOLIS - Nuwellis, Inc. (Nasdaq: NUWE), a prominent medical technology company dedicated to aiding individuals grappling with fluid overload, recently announced a significant transition in its leadership. Nestor Jaramillo, Jr. has retired from his position as President, Chief Executive Officer, and Board Director of Nuwellis, effective immediately. This change took place around mid-February 2025, marking a new chapter for the company.
John Erb Steps In as Interim President and CEO
In the wake of Mr. Jaramillo's departure, John Erb, currently serving as the Chairman of the Board, has stepped up to assume the role of Interim President and CEO. With prior experience as president and CEO of Nuwellis from November 2015 until January 2021, Mr. Erb brings valuable insight and leadership to the position. During a recent statement, Mr. Erb expressed gratitude for Mr. Jaramillo's contributions over nearly six years, acknowledging his impact on the company's growth and strategy.
Looking Ahead: The Search for a New CEO
Nuwellis is actively seeking an executive search firm to facilitate the search for a permanent CEO. This process underscores the company’s commitment to ensuring continuity and strategic direction as it navigates the rapidly evolving landscape of medical technology. Mr. Erb relayed his enthusiasm for collaborating closely with the team to address the company’s immediate priorities during this transitional period.
Mr. Erb's Contributions to Nuwellis
John Erb's tenure with Nuwellis has been marked by numerous achievements. He has been a director of Nuwellis since September 2012 and has chaired the Board since October 2012. His experience at Nuwellis is complemented by a rich history in the medical device sector, having previously served as CEO of CHF Solutions, Inc., which manufactured medical devices aimed at treating heart failure.
About Nuwellis, Inc.
Nuwellis, Inc. focuses on transforming patient care for those suffering from fluid overload. Through innovative approaches and scientific collaboration, Nuwellis aims to improve patient outcomes. The company is particularly dedicated to commercializing its Aquadex SmartFlow system, designed for ultrafiltration therapy. With its headquarters in Minneapolis and a wholly-owned subsidiary in Ireland, Nuwellis is well-positioned for growth in the medical device industry.
The Aquadex SmartFlow System
The Aquadex SmartFlow system is a clinically validated solution that offers a dependable method for the removal of excess fluid from patients with hypervolemia. This system facilitates treatment for patients whose conditions have not responded effectively to standard medical therapies or diuretics. Under the guidance of qualified healthcare providers, it can be employed either temporarily or for extended use, making it a versatile option for patient care.
Conclusion
The leadership transition at Nuwellis marks an important moment for the company as it continues to innovate and deliver effective solutions for patients with fluid overload. As John Erb leads the organization through this phase, stakeholders can anticipate a focused effort on addressing immediate needs while paving the way for long-term success.
Frequently Asked Questions
Who is replacing Nestor Jaramillo as CEO of Nuwellis?
John Erb has taken on the role of Interim President and CEO following Nestor Jaramillo's retirement.
How long did Nestor Jaramillo serve at Nuwellis?
Nestor Jaramillo served at Nuwellis for nearly six years, making significant contributions to the company.
What is the Aquadex SmartFlow system?
The Aquadex SmartFlow system is a medical device that helps remove excess fluid from patients suffering from fluid overload.
What are Nuwellis's next steps after this leadership change?
Nuwellis plans to hire an executive search firm to find a permanent CEO while continuing to focus on its operational priorities.
Where is Nuwellis headquartered?
Nuwellis, Inc. is headquartered in Minneapolis, with a subsidiary located in Ireland, enhancing its global reach.
